Resumen

Current alternatives for the treatment of major depressive disorder lack efficacy and have a delayed onset of action. Recently, the glutamatergic neurotransmission system has been noted to play an important role in the pathophysiology of this disorder. Ever since the first report of the antidepressant effects of the N-methyl-D-aspartate receptor antagonist, ketamine, research has been redirected to novel therapeutic targets. With this rapidly growing evidence of a fast-acting antidepressant such as ketamine, as well as its efficacy in treatment-resistant cases of depression, off-label use has become popular in certain settings. In this article, the clinical antidepressant properties of ketamine in relation to the glutamate hypothesis of depression are discussed, to highlight the breakthrough of these findings in the development of novel therapeutic strategies and provide a clearer view of its benefits and potential harms.

Palabras clave: Ketamine treatment-resistant depression N-methyl-D-aspartate.

2018-08-20   |   248 visitas   |   Evalua este artículo 0 valoraciones

Vol. 70 Núm.2. Marzo-Abril 2018 Pags. 65-67 Rev Invest Clin 2018; 70(2)